The Global Chemotherapy-Induced Neutropenia (CIN) Market, valued at USD 14.88 Billion in 2025, is projected to exhibit a CAGR of 5.1%, reaching USD 21.08 Billion by 2032.
Market growth is primarily driven by the rising incidence of cancer worldwide, the increasing adoption of chemotherapy as a standard treatment modality, and the growing awareness of supportive care therapies to manage treatment-related complications. Advances in biologics, granulocyte colony-stimulating factors (G-CSFs), and biosimilars, along with ongoing clinical research focused on reducing neutropenia-related complications, are further boosting the market expansion.
Additionally, the rising geriatric population, increasing healthcare expenditure, and improved access to oncology care in emerging markets are expected to sustain demand for effective CIN management solutions throughout the forecast period.
Market Takeaways
Global Chemotherapy-Induced Neutropenia (CIN) Market Report Coverage
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/chemotherapy-induced-neutropenia-cin-market
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 14.88 Billion |
|
Estimated Value by 2032 |
USD 21.08 Billion |
|
Growth Rate |
Poised to exhibit a CAGR of 5.1% |
|
Historical Data |
2020-2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Geographies Covered |
North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) |
|
Growth Drivers |
|
|
Trends |
|
|
Opportunities |
|
|
Restraints & Challenges |
|
Market Dynamics
The global chemotherapy-induced neutropenia (CIN) market is witnessing steady growth, driven by the rising prevalence of cancer worldwide, increased adoption of chemotherapy, and growing awareness of supportive care therapies to manage treatment-related complications. The oncology sector remains a key growth driver, with hospitals, cancer treatment centres, and outpatient facilities demanding effective CIN management solutions, including granulocyte colony-stimulating factors (G-CSFs), antibiotics, and antifungals. The high incidence of breast cancer and other haematological malignancies further fuels demand, as these patients are particularly susceptible to neutropenia during chemotherapy.
Technological and therapeutic advancements are reshaping the market landscape, with the development of biosimilars, long-acting G-CSFs, and novel biologics that improve patient outcomes and reduce the frequency of hospitalisations. Clinical research focused on minimizing CIN-related complications, optimizing dosing regimens, and improving patient adherence is also enhancing the market growth. Additionally, the expansion of hospital pharmacy networks and increasing availability of these therapies in emerging markets are supporting broader access to CIN management.
Despite the positive outlook, the market faces challenges such as high treatment costs, stringent regulatory requirements for biologics, and potential side effects associated with supportive care therapies. Nevertheless, continued innovation in G-CSFs, increasing healthcare expenditure, and rising investments in oncology care infrastructure are expected to sustain the market momentum.
Market Trends
The chemotherapy-induced neutropenia market is increasingly shifting toward biosimilars and long-acting formulations of granulocyte colony-stimulating factors (G-CSFs), offering cost-effective and convenient alternatives to traditional therapies. These products reduce the frequency of injections, improving patient adherence and the overall quality of care. Biosimilars are gaining regulatory approvals in major markets, providing more affordable treatment options while maintaining comparable efficacy and safety to originator biologics.
In November 2023, the U.S. FDA approved efbemalenograstim alfa-vuxw (Ryzneuta; Evive Biotech), a novel long-acting G-CSF subcutaneous injection. This Fc fusion protein–based G-CSF dimer is designed to reduce the incidence of febrile neutropenia in patients with non-myeloid malignancies undergoing myelosuppressive chemotherapy. Its approval marks a significant advancement in CIN management, offering a new therapeutic option for patients at risk of neutropenia.
Advancements in predictive analytics are transforming the management of chemotherapy-induced neutropenia (CIN) by enabling personalized risk assessment and treatment planning. By analysing patient-specific factors such as age, cancer type, chemotherapy regimen, comorbidities, and prior neutropenic events, healthcare providers can accurately predict the likelihood of febrile neutropenia and other complications. This allows clinicians to tailor prophylactic interventions, optimize dosing schedules, and minimize unnecessary treatments, ultimately improving patient outcomes and reducing hospitalizations.
Market Opportunities
The adoption of targeted therapies and immunotherapies in oncology is creating new opportunities in the chemotherapy-induced neutropenia (CIN) market by lowering the incidence of neutropenia among cancer patients. Unlike traditional cytotoxic chemotherapy, targeted therapies selectively attack cancer cells while sparing healthy bone marrow, thereby reducing the risk of myelosuppression and the subsequent need for supportive care interventions such as G-CSFs or antibiotics. This shift allows for more precise treatment regimens, fewer hospitalizations, and improved patient quality of life.
In December 2021, BeyondSpring Pharmaceuticals, a global pharmaceutical company focused on the development of cancer therapeutics, announced that it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) seeking approval of plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia (CIN). The FDA issued the CRL to indicate that they have completed their review of the application and have determined that it cannot be approved in its present form.
The integration of digital health technologies and telemedicine platforms is transforming the management of chemotherapy-induced neutropenia (CIN) by enabling the remote monitoring of patient symptoms, adherence to prophylactic therapies, and early detection of complications. Mobile health apps and electronic patient-reported outcomes (ePRO) platforms allow patients to report neutropenia-related symptoms in real time, while wearable devices can track vital signs continuously. These digital solutions alert clinicians to early signs of CIN, enabling timely interventions, optimizing treatment adjustments, and reducing the need for hospital visits or readmissions.
Analyst View
Recent Developments
Competitive Landscape
Chemotherapy-Induced Neutropenia (CIN) Market Segmentation
Regional Insights
Related Reports :